Belantamab Mafodotin Combo Sustains MRD Negativity/PFS in Multiple Myeloma
Belantamab mafodotin plus pomalidomide and dexamethasone led to a median PFS of 32.6 months in patients with relapsed/refractory multiple myeloma.
ALTERNATE Reveals Surgical Patterns After Neoadjuvant Breast Cancer Care
Axillary dissection was more likely to be omitted among patients in the ALTERNATE trial when there was 1 positive sentinel node compared with 2 or more.
Frontline Adebrelimab Shows Promise in Real-World ES-SCLC Treatment
Higher ECOG performance statuses and metastatic burden predicted poorer outcomes with frontline adebrelimab for those with extensive-stage SCLC.
How Do Experts Think Dato-DXd Should Be Used in NSCLC?
Experts discuss the proper placement of Dato-DXd in the treatment of EGFR-mutated non–small cell lung cancer, comparing it with other potential treatments.
Zanubrutinib Regimen Sustains PFS Benefit Across CLL/SLL Mutation Statuses
Data from the SEQUOIA trial support the use of zanubrutinib/venetoclax in CLL or SLL regardless of del(17p)/TP53 mutation or IGHV mutational status.
Investigational BCMA CAR-T Yields Responses/Safety in R/R Multiple Myeloma
Of the 4 patients with relapsed/refractory multiple myeloma who received KLN-1010, 1 complete response and 3 partial responses were achieved at varying levels of MRD sensitivity.
Axi-cel Produces Enduring Real-World Responses in R/R Follicular Lymphoma
Prior bendamustine exposure correlated with worse complete response rates with axi-cel among those with relapsed/refractory follicular lymphoma.
Kamdar Names Potential Treatment Options Beyond Liso-cel in R/R LBCL
The 48-month OS rate for the TRANSFORM plus long-term follow-up study was 61.5% for patients with R/R LBCL.
Pelabresib Combo Improves Efficacy Vs Ruxolitinib Alone in Myelofibrosis
The rate of 35% reduction in spleen volume or higher was higher pelabresib/ruxolitinib vs ruxolitinib alone in the MANIFEST-2 trial.
Teclistamab Combo Elicits Enduring Responses in Transplant-Ineligible NDMM
Phase 2 data support further evaluation of frontline BCMA/CD3 bispecific antibody combinations in phase 3 trials.
Anito-Cel May Have Efficient Mechanism in R/R Multiple Myeloma Treatment
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
AZD0120 Displays Early Responses/Manageable Safety in R/R Multiple Myeloma
After a median follow-up of 3.9 months, AZD0120 elicited an overall response rate of 96% among 23 patients with relapsed/refractory multiple myeloma.
Durvalumab Plus Platinum-Etoposide Displays Feasibility in ES-SCLC
Grade 3 immune-mediated AEs were observed in 11 patients with extensive-stage small cell lung cancer, which included 2 instances of pneumonitis.
Axi-Cel Yields Boosted Survival in Patients With High-Risk LBCL and 6-Month CR
The 3-year event-free survival was 88.9% and 30.0% in patients with high-risk LBCL who did and did not achieve a CR at 6 months, respectively.
High-Grade ICANS Severity Decreases Via Dexamethasone After Axi-Cel in LBCL
Data showed no significant differences in the incidence of CRS and ICANS with the use prophylactic dexamethasone in a retrospective review.
Ivonescimab/Chemo Improves Quality of Life in Frontline Squamous NSCLC
Patients with squamous NSCLC who received ivonescimab plus chemotherapy as first-line treatment had delayed deterioration in global health status.
Teclistamab/SC Daratumumab Potential New SOC in 2L R/R Multiple Myeloma
Teclistamab plus subcutaneous daratumumab yielded significant improvement in efficacy for patients with R/R multiple myeloma.
Surveying the Treatment Landscape for EGFR-Mutated Lung Cancer
An oncologist at the Georgia Cancer Center discussed the evolution of treatment strategies and emerging therapies for patients with EGFR-mutated disease.
Pirtobrutinib Improves PFS in Treatment-Naive CLL/SLL
Data from the BRUIN-CLL-313 study may support pirtobrutinib as a new potential standard of care for those with untreated CLL or SLL.
Novel Treatment Displays Tolerability in Relapsed/Refractory B-Cell ALL
A total of 45% of patients with B-cell acute lymphoblastic leukemia experienced cytokine release syndrome while receiving treatment with MK-1045, of which 3% experienced grade 3 events.
3 Things You Should Know About Future Directions for BsAbs and ADCs in NSCLC
The latest advancements in bispecific antibodies and antibody-drug conjugates continue to improve the personalized treatment of advanced non-small cell lung cancer.
Novel Microbiome-Based Therapy Safe, Tolerable in GI-aGVHD
The primary end point of GI overall response rate was met with MaaT013 for GI-aGVHD.
T-DM1 Confers Lower Cardiotoxicity Risk in HER2+ Advanced Breast Cancer
Across different studies, the highest incidence of left ventricular ejection fraction decrease was seen with trastuzumab/pertuzumab plus chemotherapy.
Sonrotoclax Elicits Responses in Relapsed/Refractory Mantle Cell Lymphoma
Data from a phase 1/2 trial support sonrotoclax as a promising treatment option in previously treated relapsed/refractory mantle cell lymphoma.
Zenocutuzumab Yields Durable Responses in Treatment-Naive NRG1+ NSCLC
Across 20 patients with treatment-naive NSCLC enrolled in the eNRGy trial who received zenocutuzumab, the ORR was 35%, with a median DOR of 17.1 months.
MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC
In the amivantamab/lazertinib arm, the median OS in the Asian population was not reached vs 38.4 months in the osimertinib arm for patients with EGFR-mutated NSCLC.
Ziftomenib Combo Exhibits Tolerability/Early Activity in NPM1/KMT2A+ AML
Among patients with NPM1-mutated and KMT2A-rearranged disease, respectively, the ORR was 65% and 41% in the phase 1 KOMET-007 trial.
Pirtobrutinib Exhibits Favorable Efficacy in R/R Follicular Lymphoma
The FDA approved pirtobrutinib as a treatment for patients with CLL/SLL who received prior BTK inhibition based on the phase 3 BRUIN-CLL-321 trial results.
RP2D Dose of Ziftomenib Yields High Response Rates in NPM1-Mutated AML
Ziftomenib given at 600 mg in combination with venetoclax/azacitidine produced high response rates in NPM1-mutated AML.
Linvoseltamab Yields High Response in Newly Diagnosed Multiple Myeloma
Linvoseltamab monotherapy achieved minimal residual disease negativity in 95% of patients with newly diagnosed multiple myeloma.
